Perampanel as precision therapy in rare genetic epilepsies
Epilepsia · 2023-04 · 64 (4) · 866-874
DOI: 10.1111/epi.17530 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Epilepsia, online erschienen am 20.02.2023. Verfasst von Andreea Nissenkorn und 33 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Neurology Unit, Wolfson Medical Center, Holon and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. Hauptthemen laut MEDLINE: Epilepsies, Partial, Epilepsy. Die Arbeit wurde bisher 47-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Objective
Perampanel, an antiseizure drug with α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazolepropionic acid receptor antagonist properties, may have a targeted effect in genetic epilepsies with overwhelming glutamate receptor activation. Epilepsies with loss of γ‐aminobutyric acid inhibition (e.g., SCN1A ), overactive excitatory neurons (e.g., SCN2A , SCN8A ), and variants in glutamate receptors (e.g., GRIN2A ) hold special interest. We aimed to collect data from a large rare genetic epilepsy cohort treated with perampanel, to detect possible subgroups with high efficacy.
Methods
This multicenter project was based on the framework of NETRE (Network for Therapy in Rare Epilepsies), a web of pediatric neurologists treating rare epilepsies. Retrospective data from patients with genetic epilepsies treated with perampanel were collected. Outcome measures were responder rate (50% seizure reduction), and percentage of seizure reduction after 3 months of treatment. Subgroups of etiologies with high efficacy were identified.
Results
A total of 137 patients with 79 different etiologies, aged 2 months to 61 years (mean = 15.48 ± 9.9 years), were enrolled. The mean dosage was 6.45 ± 2.47 mg, and treatment period was 2.0 ± 1.78 years (1.5 months–8 years). Sixty‐two patients (44.9%) were treated for >2 years. Ninety‐eight patients (71%) were responders, and 93 (67.4%) chose to continue therapy. The mean reduction in seizure frequency was 56.61% ± 34.36%. Sixty patients (43.5%) sustained >75% reduction in seizure frequency, including 38 (27.5%) with >90% reduction in seizure frequency. The following genes showed high treatment efficacy: SCN1A, GNAO1, PIGA, PCDH19, SYNGAP1, POLG1, POLG2 , and NEU1 . Eleven of 17 (64.7%) patients with Dravet syndrome due to an SCN1A pathogenic variant were responders to perampanel treatment; 35.3% of them had >90% seizure reduction. Other etiologies remarkable for >90% reduction in seizures were GNAO1 and PIGA . Fourteen patients had a continuous spike and wave during sleep electroencephalographic pattern, and in six subjects perampanel reduced epileptiform activity. Significance Perampanel demonstrated high safety and efficacy in patients with rare genetic epilepsies, especially in SCN1A, GNAO1, PIGA, PCDH19, SYNGAP1, CDKL5, NEU1 , and POLG , suggesting a targeted effect related to glutamate transmission.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pediatric Neurology Unit, Wolfson Medical Center, Holon and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
- Epilepsy Center for Children and Adolescents, Schön Clinic Vogtareuth, Vogtareuth, Germany.
- Research Institute for Rehabilitation, Transition, and Palliation, PMU Salzburg, Salzburg, Austria.
- Pediatric Neurology, University Clinic and Epilepsy Center, Frankfurt, Germany.
- Department of Epilepsy Genetics and Personalized Medicine, Danish Epilepsy Center, Filadelfia, Dianalund, Denmark.
- Department of Regional Health Research, University of Southern Denmark, Odense, Denmark.
ORCID-Profile: Andreea Nissenkorn, Susanne Schubert-Bast, Allan Bayat, Antonietta Coppola, Carlo Di Bonaventura, Martha Feucht, Georgia Ramantani, Pasquale Striano, Celina von Stülpnagel, Angelo Russo
Zitieren
APA
Nissenkorn, A., Kluger, G., Schubert-Bast, S., Bayat, A., Bobylova, M., Bonanni, P., Ceulemans, B., Coppola, A., Di Bonaventura, C., Feucht, M., Fuchs, A., Gröppel, G., Heimer, G., Herdt, B., Kulikova, S., Mukhin, K., Nicassio, S., Orsini, A., Panagiotou, M., …, & Russo, A. (2023). Perampanel as precision therapy in rare genetic epilepsies. Epilepsia, 64(4), 866-874. https://doi.org/10.1111/epi.17530
Vancouver
Nissenkorn A, Kluger G, Schubert-Bast S, Bayat A, Bobylova M, Bonanni P, et al. Perampanel as precision therapy in rare genetic epilepsies. Epilepsia. 2023;64(4):866-874. doi:10.1111/epi.17530
BibTeX
@article{Nissenkorn2023,
author = {Nissenkorn, Andreea and Kluger, Gerhard and Schubert-Bast, Susanne and Bayat, Allan and Bobylova, Marya and Bonanni, Paolo and Ceulemans, Berten and Coppola, Antonietta and Di Bonaventura, Carlo and Feucht, Martha and Fuchs, Anne and Gröppel, Gudrun and Heimer, Gali and Herdt, Brigitte and Kulikova, Sviatlana and Mukhin, Konstantin and Nicassio, Stefania and Orsini, Alessandro and Panagiotou, Maria and Pringsheim, Milka and Puest, Burkhard and Pylaeva, Olga and Ramantani, Georgia and Tsekoura, Maria and Ricciardelli, Paolo and Lerman Sagie, Tally and Stark, Brigit and Striano, Pasquale and van Baalen, Andreas and De Wachter, Matthias and Cerulli Irelli, Emanuele and Cuccurullo, Claudia and von Stülpnagel, Celina and Russo, Angelo},
title = {Perampanel as precision therapy in rare genetic epilepsies},
journal = {Epilepsia},
year = {2023},
volume = {64},
number = {4},
pages = {866--874},
doi = {10.1111/epi.17530}
}
EUVIMED